Showing results (91-100 of 204) with videos related to

Sort By:
Pageof 21
Rheumatology and Therapy|September 20, 2022
Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled TrialsMartin Bergman, Maya H Buch, Yoshiya Tanaka, et al.
The British Journal of Radiology|May 2, 2020
Feasibility of MRI based extracellular volume fraction and partition coefficient measurements in thigh muscleAlex F Goodall, David A Broadbent, Raluca B Dumitru, et al.
Rheumatology (Oxford, England)|January 29, 2025
Foot peripheral sensory neuropathy: a frequent disabling manifestation in systemic sclerosisBegonya Alcacer-Pitarch, Marco Di Battista, Anthony C Redmond, et al.
RMD Open|April 12, 2024
Understanding the psychosocial determinants of effective disease management in rheumatoid arthritis to prevent persistently active disease: a qualitative studyNkasi Stoll, Mrinalini Dey, Sam Norton, et al.
Arthritis Research & Therapy|May 30, 2019
Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA studyJanusz Jaworski, Marco Matucci-Cerinic, Hendrik Schulze-Koops, et al.
Annals of the Rheumatic Diseases|July 8, 2018
Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid ArthritisLianne Kearsley-Fleet, Rebecca Davies, Diederik De Cock, et al.
Annals of the Rheumatic Diseases|January 4, 2014
Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapySudipto Das, Edward M Vital, Sarah Horton, et al.
Heart (British Cardiac Society)|January 18, 2024
Use of coronarycomputed tomography for cardiovascular risk assessment in immune-mediated inflammatory diseasesMarta Peverelli, Robert T Maughan, Deepa Gopalan, et al.
Arthritis Research & Therapy|December 24, 2017
Profiling microRNAs in individuals at risk of progression to rheumatoid arthritisL Ouboussad, L Hunt, E M A Hensor, et al.
Rheumatology (Oxford, England)|January 12, 2021
Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritisAndrew R Melville, Md Yuzaiful Md Yusof, John Fitton, et al.
Pageof 21